<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">global-journal-of-medical-research-b-pharma-drug-discovery-toxicology-medicine</journal-id>
<journal-title-group>
<journal-title>Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology &amp; Medicine</journal-title>
</journal-title-group>
<issn publication-format="print">0975-5888</issn>
<issn publication-format="electronic">2249-4618</issn>
<publisher><publisher-name>Global Journals Publishing Group Incorporated</publisher-name></publisher>
<self-uri xlink:href="https://globaljournals.org/journal-seo-export/jats/83141.xml" />
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">83141</article-id>
<title-group>
<article-title>Varpha-K Prototype: Evolution of Anticoagulant Treatment with Improved Safety and Efficiency</article-title>
<subtitle>Development of Varpha-K to Reduce Bleeding Risks</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Souza</surname><given-names>Cassius</given-names></name><xref ref-type="aff" rid="aff1" />
</contrib>
<contrib contrib-type="author"><name><surname>Estellet</surname><given-names>SthÃ©fany</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>VitÃ³ria</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Sardinha</surname><given-names>Jonas</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Delecrode</surname><given-names>Karina</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>GraÃ§a</surname><given-names>Blenda</given-names></name></contrib>
</contrib-group>
<aff id="aff1">BRAZIL</aff>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2024-06-11">
<day>11</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>24</volume>
<issue>B1</issue>
<fpage>19</fpage>
<lpage>21</lpage>
<abstract><p>Pharmaceutical chemistry seeks to discover and develop new chemical molecules that can be useful as medicines, in addition to the possibility of improvement in some molecular physicochemical aspect. These modifications cannot alter the pharmacophoric group, which is the chemical functional group responsible for the therapeutic effects (KOROLKOVAS 1982). Thus, our objective was to present the physicochemical aspects related to the association of vitamin K with warfarin molecule (VAR), in order to develop the Varfa-K Prototype, a new drug that has fewer toxic effects, mainly reducing bleeding events caused by VAR. Therefore, we used the methodology of molecular association and insertion of bulky groups. By adding a molecule (vitamin K) to the parent drug and its own antidote against bleeding.</p></abstract>
<kwd-group kwd-group-type="author-generated">
<kwd>drug</kwd>
<kwd>disposal</kwd>
<kwd>pharmaceutical chemical residues</kwd>
<kwd>environment.</kwd>
</kwd-group>
<self-uri content-type="pdf" xlink:href="https://globaljournals.org/GJMR_Volume24/3-Varpha-K-Prototype.pdf" />
<self-uri content-type="html" xlink:href="https://globaljournals.org/scholarly-articles/varpha-k-prototype-evolution-of-anticoagulant-treatment-with-improved-safety-and-efficiency/" />
</article-meta>
</front>
<body>
<sec>
<title>Full Text</title>
<p>Pharmaceutical chemistry seeks to discover and develop new chemical molecules that can be useful as medicines, in addition to the possibility of improvement in some molecular physicochemical aspect. These modifications cannot alter the pharmacophoric group, which is the chemical functional group responsible for the therapeutic effects (KOROLKOVAS 1982). Thus, our objective was to present the physicochemical aspects related to the association of vitamin K with warfarin molecule (VAR), in order to develop the Varfa-K Prototype, a new drug that has fewer toxic effects, mainly reducing bleeding events caused by VAR. Therefore, we used the methodology of molecular association and insertion of bulky groups. By adding a molecule (vitamin K) to the parent drug and its own antidote against bleeding.</p>
</sec>
</body>
</article>